Cargando…
Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616568/ https://www.ncbi.nlm.nih.gov/pubmed/34840027 http://dx.doi.org/10.1016/j.ejca.2021.10.019 |
| _version_ | 1784604380398354432 |
|---|---|
| author | Shacham-Shmueli, Einat Itay, Amit Margalit, Ofer Berger, Raanan Halperin, Sharon Jurkowicz, Menucha Levin, Einav G. Levy, Itzchak Olmer, Liraz Regev-Yochay, Gili Lustig, Yaniv Rahav, Galia |
| author_facet | Shacham-Shmueli, Einat Itay, Amit Margalit, Ofer Berger, Raanan Halperin, Sharon Jurkowicz, Menucha Levin, Einav G. Levy, Itzchak Olmer, Liraz Regev-Yochay, Gili Lustig, Yaniv Rahav, Galia |
| author_sort | Shacham-Shmueli, Einat |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8616568 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86165682021-11-26 Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study Shacham-Shmueli, Einat Itay, Amit Margalit, Ofer Berger, Raanan Halperin, Sharon Jurkowicz, Menucha Levin, Einav G. Levy, Itzchak Olmer, Liraz Regev-Yochay, Gili Lustig, Yaniv Rahav, Galia Eur J Cancer Letter to the Editor Elsevier Ltd. 2022-01 2021-11-25 /pmc/articles/PMC8616568/ /pubmed/34840027 http://dx.doi.org/10.1016/j.ejca.2021.10.019 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Shacham-Shmueli, Einat Itay, Amit Margalit, Ofer Berger, Raanan Halperin, Sharon Jurkowicz, Menucha Levin, Einav G. Levy, Itzchak Olmer, Liraz Regev-Yochay, Gili Lustig, Yaniv Rahav, Galia Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study |
| title | Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study |
| title_full | Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study |
| title_fullStr | Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study |
| title_full_unstemmed | Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study |
| title_short | Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study |
| title_sort | letter of response to comment on: efficacy and safety of bnt162b2 vaccination in solid cancer patients receiving anti-cancer therapy - a single centre prospective study |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616568/ https://www.ncbi.nlm.nih.gov/pubmed/34840027 http://dx.doi.org/10.1016/j.ejca.2021.10.019 |
| work_keys_str_mv | AT shachamshmuelieinat letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT itayamit letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT margalitofer letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT bergerraanan letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT halperinsharon letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT jurkowiczmenucha letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT levineinavg letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT levyitzchak letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT olmerliraz letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT regevyochaygili letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT lustigyaniv letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy AT rahavgalia letterofresponsetocommentonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudy |